Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
Pricing Debate Policy Cost Effectiveness

ICER’s ‘Unsupported Price Increase’ Report Due This Fall

  • News

Executive Summary

Report by the Institute for Clinical and Economic Review will seek to inform the public policy debate on price increases for prescription drugs.

You may also be interested in...



ICER Chief Scientific Officer Bradt Brings Pharma Perspective

Pamela Brandt joins health technology assessment group after stints at Aegerion, Astellas and Abbott Labs.

Missed Opportunities: 10 Questions We Wish Senators Had Asked At The Drug Pricing Hearing

Getting seven top pharma leaders in the same room, required to answer tough questions on drug pricing, is rare. Members of the Senate Finance Committee got that opportunity recently, but there are some questions our Pink Sheet reporters think they missed.

Arnold Foundation Will Retain Drug Pricing Focus As Health Care Agenda Grows

In an interview with the Pink Sheet, Laura and John Arnold Foundation VP Health Care Mark Miller discusses the foundation’s ongoing drug pricing priorities.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
Pricing Debate Policy Cost Effectiveness
UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By